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Purpose: The primary objective of the STIC 2003 project was to
compare the clinical and economic aspects of respiratory-gated
conformal radiotherapy (RGRT), an innovative technique proposed
to limit the impact of respiratory movements during irradiation,
versus conventional conformal radiotherapy, the reference radiation
therapy for lung cancer.
Methods and Materials: A comparative, nonrandomized, multi-
center, and prospective cost toxicity analysis was performed in the
context of this project between April 2004 and June 2008 in 20
French centers. Only the results of the clinical study are presented
here, as the results of the economic assessment have been published
previously.
Results: The final results based on 401 evaluable patients confirm
the feasibility and good reproducibility of the various RGRT sys-
tems. The results of this study demonstrated a marked reduction of
dosimetric parameters predictive of pulmonary, cardiac and esoph-
ageal toxicity as a result of the various respiratory gating techniques.
These dosimetric benefits were mainly observed with deep inspira-
tion breath-hold (DIBH) techniques (ABC and SDX systems), which
markedly increased the total lung volume compared with the inspi-
ration-synchronized system based on tidal volume (Real-time Posi-
tion Management). These theoretical dosimetric benefits were cor-
related clinically with a significant reduction of pulmonary acute
toxicity, and the pulmonary, cardiac, and esophageal late toxicities,
especially with DIBH techniques. Pulmonary function parameters,
although more heterogeneous, especially DLCO, showed a tendency
to reduction of pulmonary toxicity in the RGRT group.
Conclusions: RGRT seems to be essential to reduce toxicities,
especially the pulmonary, cardiac, and esophageal late toxicities
with the DIBH methods.
Key Words: Non-small cell lung cancer, Respiratory gating,
Breath-hold techniques, Toxicities.
(J Thorac Oncol. 2011;6: 2058–2068)
Adapting radiotherapy to respiratory movements has al-ways been a major concern in chest radiotherapy. The
importance of this aspect has been further accentuated with
the development of conformal radiotherapy (CRT), with and
without intensity modulation, using reduced irradiation fields,
and especially the growing interest in stereotactic hypofrac-
tionated radiotherapy.1 These new techniques were developed
very rapidly in the 1990s as a result of progress in informa-
tion technology, but the various uncertainties of treatment,
especially related to respiratory movements, were not studied
in detail. Radiotherapists rapidly had to make a number of
choices. In the absence of precise data, they incorporated
empirical safety margins of 1.5 to 2 cm derived from con-
ventional radiotherapy.2–4 Nevertheless, the development of
these high-precision strategies, which potentially allow dose
escalation to the lung tumor volume, consequently makes
respiratory movements of the order of 1 cm unacceptable.4,5
The diffusion of respiratory gating (or breathing adapted)
techniques therefore constitutes a priority to improve the
quality and the results of radiotherapy.6
In 2003, a medicoeconomic assessment of the various
breathing adapted radiotherapy methods for the treatment of
lung cancers was conducted in the context of a project funded
by the French Ministry of Health, entitled Programme de
Soutien aux Innovations Diagnostiques et The´rapeutiques
Couˆteuses (STIC) (Expensive Diagnostic and Therapeutic
Innovation Support Program). Twenty radiotherapy depart-
ments from all over France, specialized in the treatment of
lung cancer, participated in this joint project to guide decision
makers and to provide precise data for or against the diffusion
of this innovation by comparing it with standard treatment,
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conventional CRT without respiratory gating. This study was
initiated in April 2004 according to a nonrandomized design,
but this does not constitute a limitation, as this study was
based on a pragmatic approach. At the end of the recruitment
phase, 401 patients were included: 218 patients in the respi-
ratory-gated radiotherapy group (RGRT) and 183 in the
reference group (CRT). This is the largest study to date
evaluating the various breathing adapted radiotherapy tech-
niques to optimize irradiation of lung cancers. This article
presents the general methodology of the project, setting up of
the study, and the results of the clinical study 48 months after
starting recruitment; as the results of the economic study have
already been published in a specialized journal.7,8
PATIENTS AND METHODS
Patients
This multicenter study was conducted in 13 French
cancer centers, six teaching hospitals and one nonprofit pri-
vate clinic. All patients were referred for non-small cell lung
cancer (NSCLC). The medical chart review process was
submitted to and approved by the ethical review board.
Patient inclusion criteria were as follows: histologically doc-
umented NSCLC, with or without lung resection, requiring
curative irradiation; no contraindication to thoracomediasti-
nal irradiation; satisfactory performance status (WHO score
2); chemotherapy, especially concomitant chemotherapy,
was authorized; age 18 years; forced expiratory volume in
1 second (FEV1) 1 L (or 40% of predicted) on baseline
pulmonary function tests (PFTs); absence of superior vena
cava syndrome or major pericardial effusion; and satisfactory
compliance with follow-up.
Materials and Methods
Materials
Three respiratory gating devices were tested: the Real-
time Position Management system (RPM; Varian Medical
Systems, Palo Alto); and two spirometric breath-holding
devices, the ABC active breath-holding system (Active
Breathing Control, Elekta, Stockholm, Sweden), and the SDX
deep inspiration breath-hold (DIBH) system (Dyn’R, Tou-
louse, France; Fig. 1). The RPM system monitors the pa-
tient’s respiratory cycle by means of a small plastic block
placed on the patient’s abdomen onto which two reflective
markers are fixed. These reflective markers reflect the light of
an infrared beam onto a charge-coupled device camera placed
in a fixed position in relation to the patient and connected to
a computer, in turn connected to the linear accelerator (Fig.
2). Movement of the reflectors during breathing is analyzed in
real time by software that controls triggering of the acceler-
ator according to a predefined gate.9,10,11
Spirometric breath-hold systems are based on a similar
strategy and consist of blocking the patient’s breathing,
usually in inspiration, during acquisition, or irradiation, either
voluntarily (SDX) or by occlusion of a valve (ABC). These
two techniques require a preparation phase to define the most
comfortable degree of inspiration for the patient and the
optimal breath-hold for treatment. This level usually corre-
sponds to 70% or 80% of the patient’s maximum inspiration
with a safety margin of 100 ml. These systems were the
first to be used routinely, and the original method was
initially proposed by the Memorial Sloan Kettering Cancer
Center team.12–17
Methodology
Three computed tomography (CT) acquisitions were
performed in each patient: the first two CT acquisitions were
performed with the DIBH device and the RPM system
(4DCT) to quantify the interbreath-hold variability and there-
fore the reproducibility of the device, and a final acquisition
FIGURE 1. Patient in the treatment position with the SDX
spirometric device and diagram of the breathing curve (red)
visualized by the patient with the video glasses and by the
operator. The patient visualizes the time course of lung vol-
ume (red) and the degree of breath-hold (green zone) de-
termined during a training session. After three FB cycles, the
patient is asked to achieve and maintain this DIBH level (pla-
teau phase of the red curve). CT acquisition or irradiation is
performed during this phase.
FIGURE 2. The RPM system. An infrared camera illuminates
a marker placed on the patient’s abdomen, onto which two
reflectors are fixed.
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was performed in free breathing (FB). An injection of con-
trast agent was performed during the FB acquisition to
facilitate delineation of target volumes. Target volumes were
defined according to International Commission on Radiation
Units and Measurements recommendations.18 The clinical
target volume (CTV) corresponded to the gross target volume
 8 mm (adenocarcinoma) or  6 mm (squamous cell
carcinoma) or  5 mm (other histologies).19 The internal
target volume (ITV) for the RGRT group corresponded to the
CTV  intra-RGRT variability; the intra-RGRT variability
was obtained after fusion of the two DIBH acquisitions by
combining the two CTVs. The setup margin added a 2-mm
safety margin to the ITV, resulting in the final planning target
volume (PTV; Figure 3). The total dose to the PTV had to be
situated between 65 and 70 Gy (1.8 and 2.2 Gy per fraction)
with a homogeneity of 7%/5%. Dose constraints were as
follows: maximum dose (Dmax) to the spinal cord: 45 Gy;
volume of the two lungs minus PTV receiving a dose of at
least 20 Gy (V20): less than 37% (V2037%); and volume of
esophagus receiving a dose of at least 50 Gy (V50): less than
35% (V5035%). For the CRT group, ITV corresponded to
CTV  3 mm for an upper or middle lobe tumor and CTV 
8 mm for a lower lobe tumor, and the setup margin corre-
sponded to ITV  2 mm.
The daily reproducibility was assessed by electronic
portals acquisitions performed for all patients according to
the following protocol: the first 3 days and then twice a week
until the end of radiation. The tolerance limits were 3 mm in
all planes. The anatomical lines of reference were as follows:
The trachea and carina, the two clavicles, the two pulmonary
apices, and the vertebral column for the anteroposterior
images.
The trachea, the two pulmonary apices, the vertebral column,
and the posterior chest wall for the lateral images.
Common Quality Assurance Program
The 20 participating institutions developed common
procedures to standardize quality assurance and all quality
controls during the various steps of respiratory gating
techniques.20
Endpoints
The first step of this study consisted of verifying that
the various RGRT devices were reliable and reproducible.
For this purpose, data of the two acquisitions performed with
one of the RGRT systems were compared. Analysis of CTV
reflects reproducibility of the systems in terms of the tumor
and would seem to be the most relevant, because it is directly
related to the precision and reproducibility objectives of
RGRT. Nevertheless, the results of this analysis are highly
dependent on contouring uncertainties. Total lung volume
(TLV), usually estimated by automatic lung contouring, was
also tested, as it is probably more representative of the
reproducibility of RGRT techniques.
All patients were regularly evaluated according to ob-
jective and standardized criteria and methods of clinical
evaluation. For all patients, the initial staging included a chest
and upper abdomen CT scan, a CT scan and/or an magnetic
resonance imaging of the brain, and a PET scan. In addition,
the specific evaluation for this study consisted of physical
examination, chest x-ray, PFT with plethysmography and
determination of the diffusing capacity of the lung for carbon
monoxide (DLCO), and chest CT scan at baseline and then at
3, 6, 12, 18, and 24 months.
Safety was the major end point evaluated according to
common parameters and scales in all 20 institutions: Radia-
tion Therapy Oncology Group classification for evaluation of
acute toxicity and Late effects of Normal Tissues (Subjective,
Objective, Management, Analytic) classification for evalua-
tion of late toxicity (esophagus, lung, and heart), PFT results,
and the rate of grade 2 radiation pneumonitis. Only the
highest grade in each category of the Radiation Therapy
Oncology Group and Late effects of Normal Tissues (Sub-
jective, Objective, Management, Analytic) classifications was
recorded at each evaluation for each organ analyzed.21,22 The
other endpoints were as follows:
Clinical endpoints: local control (RECIST criteria), recur-
rence-free survival, and overall survival.
Dosimetric endpoints: mean dose (Dmean), minimum dose
(Dmin), maximum dose (Dmax), dose to 95% and 5% of the
volume (D95 and D05) in PTV; calculation of lung V20,
V25, V37, and Dmean; cardiac Dmean, Dmax, and V40; and
esophageal V50, EL50, EL60 (length of esophagus receiving
a dose of 50 Gy and 60 Gy, respectively), Dmean and Dmax.
Statistical Analysis
Statistical analysis was performed by R software R.23
Descriptive data analysis was performed. Qualitative vari-
ables were described by sample sizes and corresponding
percentages, and quantitative variables were described by
their mean, median, and standard deviation. In bivariate
analyses, qualitative variables were studied by 2 test or
Fisher’s exact test, and quantitative variables were studied by
Student t test or Kruskal-Wallis test, as appropriate. Quanti-
tative variables for which two successive measures were
available were analyzed by a concordance test. Survival
FIGURE 3. Target volumes in axial (A), coronal (B), sagittal
(C), and 3D views defined according to the protocol recom-
mendations: GTV (red), CTV (blue), ITV (green), and set-up
margin (yellow).
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curves were estimated by the Kaplan-Meier method and were
compared by the log-rank test. PFT parameters (TLV, DLCO,
and FEV1) were expressed as a percentage of the difference
between the posttreatment value and the baseline value over
the baseline value. Results were considered to be significant
for p  0.05.
RESULTS
Four hundred one patients were included in the study.
Table 1 shows patient characteristics in the two treatment
groups. The median age was 65 years (range, 57–87 years).
The histology most frequently encountered was squamous
cell carcinoma (49%) followed by adenocarcinoma (34%).
Tumors were mostly located in the right lung (62%) and in
the upper lobe (62%). In terms of TNM stage, most tumors
were stage T2-T3 (63%) and N2 (44%). Neoadjuvant che-
motherapy had been administered before radiotherapy in 69%
of cases. Concomitant chemotherapy was proposed in 49% of
cases. Three hundred eighty patients (94.7%) were smokers
or ex-smokers before the diagnosis of lung cancer and 95% of
smokers continued smoking during radiotherapy. The median
follow-up was 25 months (range, 0–39 months).
Forty-five percent of patients were treated by CRT
(183) and 55% were treated by RGRT (218). Among the
various respiratory gating systems used, 78% of patients
included in the RGRT group were treated with the SDX, 15%
with the ABC, and 7% with the RPM systems. Fifty-five per
cent of patients were treated with an arm support (arm above
the head) and alpha cradle immobilization. The majority of
patients (65%) were irradiated with a photon beam with a
maximum energy greater than 18 MV. The median prescribed
dose was 66 Gy (range, 6–79 Gy) over a median duration of
50 days (range, 4–79 days).
The RGRT group comprised more patients with respi-
ratory failure than the CRT group (68 versus 32%, p 0.02).
Nevertheless, no difference was observed in terms of FEV1
and VC. As this study was not randomized, the investigators
naturally included patients with more severe respiratory fail-
ure in the RGRT group. Similarly, the RGRT group com-
prised significantly more patients with T1/T2 tumors than the
CRT group (56% versus 40%, p  0.006), resulting in a
larger proportion of small tumors, potentially more mobile
with breathing, in the RGRT group. No difference in terms of
N stage was observed between the two groups. All the classic
parameters such as T and N stage, previous history, smoking
status, and especially tumor location (localization on lobe)
have been tested and did not show up as significant factors for
acute and late toxicities and efficacy.
Feasibility
Compliance
Eighty-eight percent of patients scheduled to receive
RGRT were treated with this technique. Twenty-one patients
initially scheduled to receive RGRT were finally treated with
FB. These changes were because of an insufficient respiratory
capacity to use a breath-hold system (ABC or SDX) in 12
patients, very poor performance status in two patients, and
poor understanding of the breath-hold technique in seven
patients.
Analysis of the Reproducibility of Respiratory
Gating Systems
An excellent correlation was observed between the two
respiratory-gated CT acquisitions for CTV and TLV. These
results confirm theoretical studies conducted by the quality
assurance group on various phantoms.24 This correlation
between the two respiratory-gated CT acquisitions allowed
TABLE 1. Patient Characteristics
Characteristics All CRT RGRT p
Age
Median 65 67 64 NS
Range 57–87 42–86 33–87
Gender
Male 334 154 180 NS
Female 67 29 38
Histology
SCC 198 90 108 NS
ADC 138 60 78
Other 65 33 32
Affected side
RUL 151 71 80 NS
RML 24 7 17
RLL 70 39 31
LUL 106 52 54
LLL 50 14 36
TNM stage
T1 46 12 34 0.006
T2 143 59 84
T3 103 55 48
T4 85 44 41
Tx 24 13 11
N0 111 45 66 NS
N1 24 9 15
N2 184 88 96
N3 82 41 41
Smoking
Ex-smokers 380 174 206 NS
Current smokers 361 166 195
Respiratory insufficiency
Yes 207 59 148 0.02
Chemotherapy
Neoadjuvant 275 137 138 NS
Concomitant 197 97 100
Radiotherapy
Type 401 183 218
SDX 171
ABC 32
RPM 15
WHO performance status
0 190 82 108 NS
1 168 68 100
2 43 33 10
NS, not significant; p, difference between RGRT and CRT.
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comparison of dosimetric parameters measured in CRT with
the mean parameters measured during the two respiratory-
gated acquisitions.
Individual analysis of the three devices used in this
study showed a good concordance between the measured
CTV values and TLV during two respiratory-gated acquisi-
tions (Figure 4). Nevertheless, absolute values of the corre-
lation coefficients for the two breath-hold systems (ABC and
SDX) were better than for RPM, but this difference is
difficult to interpret in view of the small number of patients
treated by RPM.
Analysis of Dosimetric Data
Tumor Target Volumes
CTV were comparable in CRT and in RGRT. Never-
theless, as a result of the protocol, ITV and PTV were
significantly smaller in the RGRT group. The difference in
PTV between RGRT and CRT was 282  176 ml versus
360  232 ml, respectively (p  0.00001). The dosimetric
coverage of CTV and PTV tumor-target volumes was com-
parable with the two modes of radiotherapy. Nevertheless,
differences in mean values of PTV D95 and D5 were signif-
icantly higher in the RGRT (Table 2).
Lungs
TLV was significantly greater during DIBH acquisi-
tions (mean of 1421 ml, 5371  1485 ml versus 3949 
1272 ml, p  0.00001). This marked increase of healthy lung
volume because of inflation by the various DIBH techniques
resulted in a significant reduction of the following dosimetric
parameters: V20 (22.8% versus 26.5%, p  0.0001), V25
(18.8% versus 23.2%, p  0.0001), V37 (11.8% versus
15.1%, p  0.0001), Dmax (69 Gy versus 70 Gy, p  0.04),
and Dmean (12.8 Gy versus 15.6 Gy, p  0.0001) between
RGRT and CRT, respectively (Table 2, Figure 5).
Heart
Total heart volume was significantly different accord-
ing to the mode of irradiation: 638  171 ml versus 697 
190 mL in RGRT and CRT, respectively (p  0.0001). This
reduction of heart volume observed in the RGRT group can
be explained by relative compression of the heart by the two
FIGURE 4. Correlation curves be-
tween two consecutive respiratory-
gated CT acquisitions with (A) all
respiratory gating devices and (B)
for the three devices separately an-
alyzed for CTV and TLV.
TABLE 2. Dosimetric Parameters
Volumes CRT RGRT p
PTV
Volume (cm3) 360  229 282  176 0.00001
Dmax (Gy) 70.1  5.7 69.9  5.6 NS
Dmean (Gy) 58.5  7.6 57.8  6.9 NS
D95 (Gy) 60.1  36.1 61.0  9.9 0.0001
D5 (Gy) 63.9  11.8 64.5  8.9 0.001
Lungs
Volume (cm3) 3949  1272 5371  1485 0.00001
V20 (%) 26.5  12.5 22.8  9.6 0.0001
V25 (%) 23.2  10.8 18.8  8.2 0.0001
V37 (%) 15.1  8.1 11.8  5.7 0.0001
Dmean (Gy) 15.6  7.7 12.8  5.1 0.0001
Heart
Volume (cm3) 697  190 638  171 0.0001
V40 (%) 11.5  13.7 8.1  10.6 0.0001
Dmax (Gy) 55.3  21.8 51.5  23.5 0.0001
Dmean (Gy) 13.1  10.3 10.9  9.2 0.0001
Esophagus
EL50 (cm) 7.1  4.7 6.6  4.6 0.0001
EL60 (cm) 5.8  4.4 5.4  5.2 0.001
V50 (%) 25.5  20.4 22.6  18.3 0.0001
Dmax (Gy) 59.1  17.4 58.4  18.1 0.0001
Dmean (Gy) 24.4  12.2 22.5  11.3 0.0001
NS, not significant; p, difference between RGRT and CRT.
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lungs in DIBH. Dmax, Dmean, and V40 were significantly lower
in the RGRT group (Table 2, Figure 6).
Esophagus
Dmax and Dmean were significantly higher in the CRT
group than in the RGRT group: 59.1  17.4 Gy versus
58.4  18.1 Gy (p  0.0001) and 24.4  12.2 Gy versus
22.5  11.3 Gy (p  0.0001), respectively. The other
dosimetric parameters measured were also lower in the
RGRT group (Table 2).
Toxicity
Acute Toxicity
Overall, 74% of patients experienced at least one form
of clinical toxicity, usually esophagitis (65%); 34% of pa-
tients experienced pulmonary toxicity, 26% experienced cu-
taneous toxicity, and 1.7% experienced cardiac toxicity. No
significant difference was observed in terms of acute
toxicity between the two groups except for pulmonary
toxicity, which was more frequent in the CRT group than
in the RGRT group (48% versus 36%, p  0.02). No
significant difference was observed in terms of grade. The
other cutaneous, esophageal, and cardiac toxicities were
identical in the two groups (Table 3).
Late Toxicity
In the overall population, clinical pulmonary toxicity
decreased regularly throughout follow-up with a peak
incidence at the 3-month and 6-month assessments (Table
3). Overall, 61% of patients did not experience any pul-
monary toxicity. PFTs performed after 24 months of fol-
low-up showed a marked reduction of DLCO (median,
37%) and a less marked reduction of FEV1 (median,
12.5%) and TLV (median, 10.4%) in the overall pop-
ulation. Cardiac and esophageal toxicity is described in
detail in Table 3.
At the 3-month assessment, the only significant be-
tween-group differences concerned the number of hospital-
izations (CRT: 24% versus RGRT: 14%, p  0.01) and the
number of consultations (CRT: 67% versus RGRT: 56%, p
0.04). From the 6th month onward, the incidence of grade3
toxicity was higher in the CRT group than in the RGRT group
(9% versus 6%, p  0.03). A significant difference in the
esophageal toxicity was also observed between the two
groups with 2.7% in the RGRT group versus 7% in the CRT
group. No significant difference in terms of toxicity was
observed between the two groups at the following assess-
ments. Analysis of PFT parameters did not reveal any signif-
icant difference between the two groups at the various as-
FIGURE 5. Comparison of TLV
distribution and of the lung volume
receiving a dose of at least 25 Gy
(V25) according to the respiratory
gating technique: with (RGRT) or
without (CRT) respiratory gating.
FIGURE 6. Comparison of distri-
butions of the Cardiac Dmax and
V40 between a radiotherapy tech-
nique with (RGRT) or without
(CRT) respiratory gating.
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sessments. Nevertheless, a tendency to deterioration of
DLCO, FEV1, and TLV was observed at the 24th month in
the CRT group (Table 3).
Efficacy
After a median follow-up of 26 months (range, 1–47
months), 169 patients were alive (43%), 14 had been lost to
follow-up (4%), and 208 patients had died (53%). A total of
244 patients (64%) experienced disease progression after
radiotherapy. One hundred fifty-eight (43%) of these patients
developed metastatic disease and 34% developed local recur-
rence, in irradiation fields in 94 cases (88%) and outside of
irradiation fields in 12% of cases. Twenty-seven percent of
patients experienced synchronous metastatic and local pro-
gression. Among the causes of death, 159 patients (76%) died
of lung cancer, 13% died of intercurrent infection, and 11%
died of another cause or an unknown cause. The majority of
cases of disease progression occurred during the first year
(90%). Local recurrences predominantly occurred between
the 3rd and 12th months with no difference in the distribution
between recurrences inside and outside of irradiation fields.
Metastatic disease progression was mainly observed during
the first year (78%), especially during the first 6 months
(62%). Figure 7 presents overall survival and specific sur-
vival curves, disease-free interval, and metastasis-free inter-
val in the overall population treated for lung cancer. No
significant difference of efficacy was observed between the
two groups in terms of overall survival, specific survival, or
disease-free interval.
Comparison of the Three Respiratory Gating
Techniques
The three groups were strictly comparable except in
terms of tumor size, with significantly more T1/T2 tumors in
the RPM group than in the SDX and ABC groups (73%
versus 58.1% versus 25.4%, p  0.02). Patients treated with
one of the DIBH techniques had lower FEV1 and VC values
than patients in the RPM group. These findings confirm the
selective inclusion of patients with more severe respiratory
TABLE 3. Acute and Late Toxicities
Organs Date Grades CRT (%), n  183 RGRT (%), n  218 p
Lungs Acute Grade 1–2 85 (46) 74 (34) 0.02
Grade 3–4 3 (1.6) 5 (2.2)
6th mo Grade 1–2 43 (23) 51 (23) 0.03
Grade 3–4 17 (9) 13 (6)
12th mo Grade 1–2 30 (16) 35 (16) NS
Grade 3–4 7 (3.8) 11 (5)
24th mo Grade 1–2 15 (8) 20 (9) NS
Grade 3–4 5 (2.7) 4 (1.8)
PFT (difference between pretests in %) 6th mo FEV1 7.3  20.7 26.3  268.1 NS
DLCO 16.6  38.6 26.1  148.4 NS
TLV 9.3  15.4 36.9  240.4 NS
12th mo FEV1 7.1  27.4 4.8  25.2 NS
DLCO 20.5  178.1 4.6  124.4 NS
TLV 8.8  16.9 8.3  20.2 NS
24th mo FEV1 13.8  19.6 3.6  21.3 NS
DLCO 66.8  21.8 17.3  66.2 NS
TLV 7.9  15.5 1.5  35.7 NS
Heart Acute Grade 1–2 4 (2.1) 3 (1.3) NS
Grade 3–4 0 0
6th mo Grade 1–2 0 2 (0.9) NS
Grade 3–4 0 0
12th mo Grade 1–2 2 (1.1) 2 (0.9) NS
Grade 3–4 0 1 (0.4)
24th mo Grade 1–2 1 (0.5) 0 NS
Grade 3–4 0 0
Esophagus Acute Grade 1–2 118 (64.5) 128 (58.7) NS
Grade 3–4 6 (3.2) 11 (5)
6th mo Grade 1–2 12 (5.5) 6 (3.2) 0.04
Grade 3–4 1 (0.5) 0
12th mo Grade 1–2 0 2 (0.9) NS
Grade 3–4 0 0
24th mo Grade 1–2 0 0 NS
Grade 3–4 0 0
NS, not significant; p, difference between RGRT and CRT.
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failure and more advanced tumors in the ABC and SDX
DIBH groups.
Analysis of Dosimetric Data
As expected, TLV was significantly greater on acqui-
sitions using a DIBH system (ABC and SDX) than on
acquisitions using the inspiration-synchronized system
(RPM; mean, 2400 mL; ABC: 5510  1064 mL versus
SDX: 5540  1426 mL versus RPM: 3106  602 mL; p 
0.00001). This increase of TLV resulted in a significant
reduction of V20 and V25 between the SDX and ABC
systems versus the RPM system (Figure 8). A tendency to
reduction of Dmean and V37 was also observed. No signif-
icant difference of dosimetric parameters was observed for
the heart and esophagus (Table 4). Despite a different
stage distribution between the three groups on inclusion,
CTV and PTV were not significantly different between the
groups. The dosimetric coverage of the CTV and PTV,
evaluated in terms of Dmax, Dmean, D95, and D5, was
similar with the various techniques.
As the ABC and SDX systems are very similar in terms
of their DIBH technique, they were considered together for
subsequent comparisons with RPM. Grouping of these two
techniques accentuated the differences observed between the
various systems (Table 4).
For the lungs, a significant reduction of all dosimetric param-
eters predictive of pulmonary toxicity was observed with
DIBH systems.
For the heart, a significant difference was demonstrated in
terms of potential cardiac toxicity.
For the esophagus, the same tendency was confirmed and was
statistically significant after combining the ABC and SDX
groups, i.e., a reduction of Dmax, Dmean, and V50.
Acute Toxicity
Overall, a higher hospitalization rate but fewer special-
ist consultations were observed during radiotherapy in the
RPM group than in the other two groups. Nevertheless,
esophageal, cardiac, and pulmonary toxicities were identical
in the three groups. Identical results were observed after
combining the two DIBH groups.
Late Toxicity
No significant difference in terms of clinical toxicity or
PFT was observed between the three groups at the subsequent
assessments.
FIGURE 7. Overall (A) and dis-
ease-free (B) survival (log-rank test)
according to the radiotherapy tech-
nique with (RGRT) or without (FB)
respiratory gating.
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Efficacy
No significant difference of efficacy in terms of overall
survival, specific survival, and disease-free interval was ob-
served between the three groups. The local recurrence rate
was 43.3% in the ABC group, 36.7% in the SDX group, and
13% in the RPM group. The distribution of local recurrences
inside or outside of irradiation fields was as follows: ABC:
82% versus 18%; SDX: 88% versus 12%; RPM: 50% versus
50%. Identical results were observed after combining the two
DIBH groups.
DISCUSSION
The STIC project, based on a large number of patients
with a long follow-up, confirms the preliminary results pub-
lished on the various respiratory gating devices derived from
smaller patient series.12,13,17,25–27 The primary objective of this
study was to compare the clinical and economic aspects of
respiratory-gated conformal radiotherapy (RGRT), an innova-
tive technique proposed to limit the impact of respiratory move-
ments during irradiation, versus conventional CRT, the ref-
erence radiation therapy for NSCLC. This study is not
randomized but is the result of a pragmatic and free choice of
the different teams according to the availability of these
techniques in the 20 participating centers and on patient-
related (frail patient, respiratory insufficiency, but able to
maintain apnea: PS0 or 1…) or tumor-related (small tumor
size, middle or lower lobe, mobile with respiration …)
criteria. In the end, the two groups differed only according to
size (smaller and consequently more favorable to RGRT) and
respiratory insufficiency (more severe in the RGRT group).
The final results based on 401 evaluable patients confirm the
feasibility and good reproducibility of the various respiratory
gating systems, regardless of tumor site. The results of this
study demonstrated a marked reduction of dosimetric param-
eters predictive of pulmonary, cardiac, and esophageal tox-
icity as a result of the various respiratory gating techniques.
These dosimetric benefits were mainly observed with DIBH
techniques (ABC and SDX systems), which markedly in-
creased the TLV compared with the inspiration-synchronized
system based on tidal volume (RPM); however, this differ-
ence must be interpreted in view of the small number of
patients treated by RPM. With a median follow-up of 25
months, these theoretical dosimetric benefits were correlated
clinically with a significant reduction of toxicity, pulmonary
acute toxicity, and pulmonary, cardiac, and esophageal late
toxicities. Pulmonary function parameters, especially DLCO,
although more heterogeneous, showed a tendency to reduc-
tion of pulmonary toxicity in the RGRT group. The clinical
results show that the treatment of lung cancer has a limited
efficacy and is relatively toxic. The large number of local
recurrences with irradiation fields associated with consider-
able pulmonary and esophageal toxicity confirm the need for
very precise irradiation techniques to increase the dose de-
livered to the target volume, while ensuring optimal protec-
tion of adjacent healthy tissues.
Published studies comparing the various respiratory
gating methods show that they all provide a real clinical
benefit and that each technique has its own specifici-
ties6,25,26,28 and indications in the various situations encoun-
tered in routine clinical practice. Nevertheless, DIBH tech-
niques are more widely used throughout the world than
synchronized techniques.12,13,17,25,27
Nevertheless, the use of RGRT requires additional
resources in terms of patient preparation and teaching of
DIBH techniques, and especially in terms of treatment ses-
sions which are an average of several minutes longer than
conventional techniques, resulting in increased demands on
personnel and equipment.1,6,8,29,30
All respiratory gating methods also benefit from the
contribution of image-guided radiotherapy.29,31 Just like bone
alignment techniques, visualization of the real position of the
target volume during breathing improves the overall quality
of radiation therapy. Although the implementation of one or
more respiratory gating techniques was initially motivated by
the need to limit respiratory movements, these techniques
now allow new modalities of irradiation, such as hypofrac-
tionated and intensity-modulated radiotherapy.5,27,32 Sophis-
ticated and more or less dedicated apparatuses, such as
Novalis TX (BrainLAB, Feldkirchen, Germany), Cyberknife
(Accuray, Sunnyvale), or dynamic arc therapy, combined
with an appropriate respiratory gating technique are already
operational. Tomotherapy (Tomotherapy, Madison) should
also be available in the near future.5,6
CONCLUSION
Respiratory-gated radiotherapy seems to be essential
to reduce acute and late toxicity, especially pulmonary
acute toxicity, and pulmonary, cardiac, and esophageal late
toxicities during chest irradiation. DIBH respiratory gating
techniques seem to be more efficient than synchronized
systems to reduce these various toxicities, at least in terms
FIGURE 8. Comparison of TLV distribution according to
three devices (ABC, SDX, and RPM) separately analyzed.
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of dosimetric parameters. From the economic point of
view, RGRT induces excess equipment and running costs,
which must be taken into account in the fee structure to
encourage the development and routine use of these
techniques.
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